Smoking Cessation Market to 2030 – Insights, Epidemiology, and Forecast – | Financial Buzz

Smoking Cessation Market to 2030 – Insights, Epidemiology, and Forecast –

The “Smoking Cessation-Market Insights, Epidemiology, and Market Forecast-2030” drug pipelines has been added to’s offering.

This report delivers an in-depth understanding of the Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Smoking Cessation market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Smoking Cessation market size from 2017 to 2030. The Report also covers current Smoking Cessation treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.

The treatment of smoking includes various options such as nicotine replacement therapy (NRT), non-nicotinic pharmacological therapies, behavioral therapies, and counseling.

Varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Nortriptyline and clonidine are also used in smoking cessation as off-label medicines.

In the United States, NRT is available over the counter or by prescription as patches, gum, and lozenges, and by prescription only as a nasal spray and oral inhaler. NRT provides nicotine to reduce withdrawal symptoms, including irritability, anxiety, difficulty concentrating, dysphoria, hunger, weight gain, and sleep disturbances, which occur when a smoker stops smoking.

Non-pharmacological treatments for tobacco dependence include behavioral skills training using cognitive behavioral therapy techniques, motivational interviewing, and incentives to motivate and reinforce behavior change.

Smoking Cessation Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers and Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Key Findings

  • The total diagnosed prevalent population of Smoking Cessation in the 7MM was 49,301,950 in 2017.
  • The United States showed the highest diagnosed prevalent cases of smokers, as compared to EU5, and Japan. In 2017, the number of smokers in the US was estimated to be 35,288,932.
  • In the US, there were 19,303,046 diagnosed prevalent cases of smokers among males and 15,985,886 diagnosed prevalent cases among females in 2017.
  • Out of the total 35,288,932 diagnosed prevalent cases of smokers in the US, the highest cases were observed in the age group 45-64 years (14,080,284) and the least cases were observed in 18-24 years (3,140,715) in the year 2017.
  • Among the European-5 countries, Germany had the highest diagnosed prevalent population of smokers with 19,305,099 cases, followed by France with 14,044,812 cases. On the other hand, the United Kingdom had the lowest diagnosed prevalent population of 7,750,777 in 2017.
  • Japan had 19,411,835 diagnosed prevalent cases of smokers in 2017, and out of this approximately 5,610,020 diagnosed cases of smoking cessation were estimated.

Key Findings

  • The market size of Smoking Cessation in the 7MM was USD 2,874.8 million in 2017.
  • According to the estimates, the highest market size of smoking cessation is found in the United States, followed by Japan and France.
  • The current market for Smoking Cessation includes three major therapies Varenicline (Chantix), Bupropion-SR (Zyban), and nicotine replacement therapies (NRT). NRT includes inhaler, nasal spray, patch, gum, and lozenge.
  • The emerging therapies for Smoking Cessation include AXS-05, Cytisinicline, and NFL-101, which are expected to enter the market during the forecasted period (2020-2030).
  • Among the EU-5 countries, France has the highest market size of USD 151.3 million, followed by Spain and the United Kingdom in 2017. The lowest market size was estimated in Germany with USD 77.8 million in 2017.
  • The total market size of Smoking Cessation in Japan was estimated to be USD 333.5 million in 2017

Report Highlights

  • The increasing diagnosed prevalence of the Smoking Cessation along with promising emerging pipeline therapies will positively drive the Smoking Cessation market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation R&D.
  • Major players are involved in developing therapies for Smoking Cessation. The launch of emerging therapies will significantly impact the Smoking Cessation market.
  • The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

  • Pfizer
  • GlaxoSmithKline
  • Axsome Therapeutics
  • Achieve Life Sciences
  • Chronic Airway Therapeutics
  • Smoke Free Therapeutics (NFL Biosciences SAS)
  • Novo Nordisk

For more information about this drug pipelines report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!